DUBLIN--(BUSINESS WIRE)--The "Osteoporosis Therapeutics in Asia-Pacific Markets to 2024 - Growth Driven by Ongoing Transition from Anti-Resorptive Agents to Anabolic Therapies, Rising Prevalence, and Growing Awareness." report has been added to ResearchAndMarkets.com's offering.
The chronic nature of osteoporosis, which requires ongoing treatment, relatively high annual cost of therapy (ACoT) of premium therapies, increasing prevalence and awareness about the disease among the patients over a period of time, and growing demand for mainly anabolic therapies, with only one anabolic therapy currently available in the market, have made osteoporosis treatment a highly lucrative market.
The osteoporosis therapeutic market has become very competitive due to the high number of new drug approvals, although the majority of them are incremental innovations of existing therapies. Competition is fierce, particularly among bisphosphonates and selective estrogen receptor modulators (SERMs), which are mostly used as first-line therapy and dominate the treatment market for osteoporosis patients.
Lack of effective and safe therapeutic options to treat osteoporosis was the major reason for development of currently marketed premium anabolic therapies. The competition among the premium therapies is expected to intensify during the forecast period due to expected launch of pipeline products. Additionally the expected launch of biosimilars will add fuel to the intense competition and make it tough for premium therapies to gain market share in the forecast period.
Patient compliance for osteoporosis therapies is a major unmet need, as the disease is asymptomatic until a fracture occurs and requires ongoing treatment. Drug delivery is crucial in the choice of medication.
Most medicines are administered orally, while others are administered intranasally or through injections. Medications with decreased dosing are often the preferred options. Therefore convenient and safe administration without significant compromise of therapy efficacy remains an unmet need.
The current Asia-Pacific osteoporosis market contains novel products,
including a humanized anti-sclerostin mAb, a synthetic peptide analog
of human PTHrP, and a recombinant peptide and analogue of PTH.
Bisphosphonates and SERMs dominate the osteoporosis market. However,
unmet needs exist in terms of safety and efficacy.
The pipeline contains a range of molecule types and molecular targets,
including those that are well established in osteoporosis, and novel,
first-in-class therapies. There are over 136 active pipeline
molecules, and most of the late-stage investigational drug candidates
feature improved dosing regimens and administration routes in
comparison to currently marketed products and combination therapies.
Analysis of clinical trials since 2006 identified that the failure
rates of osteoporosis molecules were highest in Phase III, with the
overall attrition rate for osteoporosis standing at 83%.
Over the 2017-2024 forecast period, the Asia-Pacific osteoporosis
therapeutics market is expected to increase in value at a compound
annual growth rate of 5.9%.
A rising osteoporosis prevalence population and the uptake of newer
therapies will lead to significant market growth over the forecast
period, despite the launch of biosimilars.
Various drivers and barriers will influence the market over the
Licensing deals are the most common form of strategic alliance in the
osteoporosis therapeutics market, with deal values ranging from under
$10m to over $200m.
- Warner Chilcott
- Merck & Co.
- Astellas Pharma
- Procter & Gamble
- Sumitomo Pharmaceuticals
- Eli Lilly
Key Topics Covered
1 List of Tables & Figures
3 Marketed Products
4 Product Pipeline
5 Clinical Trial Analysis
6 Multi-Scenario Forecast
7 Market Dynamics (Drivers and Barriers) of Osteoporosis Therapeutics Market
8 Deals & Strategic Consolidations
For more information about this report visit https://www.researchandmarkets.com/research/trbqm8/osteoporosis?w=4